294 results about "Low density lipoprotein cholesterol" patented technology

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and / or reduction of homocystein and / or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

The invention relates to blood lipid-lowering active fractions of forsythia suspensa and a preparation method and use of the same. The active fractions are ethyl acetate fractions obtained by concentrating an extract which is extracted from forsythia suspensa leaves by acetone and water. The compound of phillygenin prepared by the invention and the active fractions, namely the ethyl acetate fractions, at which the phillygenin is positioned have good antioxidant activity in vitro. In-vivo experiments show that the ethyl acetate fractions and the phillygenin can lower total cholesterols and low-density lipoprotein cholesterin in the blood serum of a mouse with hyperlipidemia and can lower blood lipid level by an oxidative approach (raising superoxide dismutase SOD and lowering malonydialdehyde MDA). In addition, the ethyl acetate fractions have a better effect of reducing the total cholesterols in the blood serum of the mouse than the phillygenin and cassia seed blood lipid-lowering tablets. The ethyl acetate fractions of the forsythia suspensa leaves can be further developed to play a role in the multi- target co-prevention and treatment of hyperlipidemia and other diseases and have a good application prospect.

The invention relates to an application of lactobacillus plantarum in preparation of food, health food, a health product or a medicine with a function of reducing blood fat or assisting fat-reducing. The collection number of the lactobacillus plantarum is CGMCC No.8198. the lactobacillus plantarum was collected in China General Microbiological Culture Collection Center (CGMCC) on Sep. 17, 2013. The address is 1 Beichen West Road, Chaoyang District, Beijing. The strain achieves the effect of reducing blood fat by reducing the level of serum cholesterol, triglyceride and low-density lipoprotein cholesterin. L.plantarum CGMCC No.8198 and its fermented products also play a role in controlling and reducing weight, and have an effect of assisting fat-reducing. The invention provides a biological therapy for effectively reducing serum cholesterol and assisting fat-reducing. The biological therapy has long-term eating safety and has a considerable application prospect.

The invention provides a human blood fat (serum / plasma) quality management reference kit. The kit takes human serum (plasma) as a matrix; a human blood fat component (human apolipoprotein A1 antigen, apolipoprotein B antigen, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and the like), a stable system and an anticorrosion system are added to the matrix; the stable system is any combination of a surfactant of Triton series, Tween series, EDTA (ethylene diamine tetraacetic acid) series and the like, a polymer of polyvinyl alcohol series, polyvinylpyrrolidone series, polyethylene glycol series and the like, and a phosphate buffer solution; and the anticorrosion system is any combination of sodium azide, gentamicin, amphomycin and ProClin series. The invention further provides a preparation method of the kit. The kit is free from medium effect interference, is used for quality control and evaluation between the detection systems, and more really reflects actual quality conditions of human serum (plasma) samples, which are detected by detection systems.

The invention discloses a kit for detecting high density lipoprotein cholesterol. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises the following components of the corresponding concentrations: 10-100 mmol / L buffer solution I, 0.1-10 mmol / L polyanionic compound, 0.1-100 mmol / L bivalent cation, 0.1-10 mmol / L developer, 1-100 g / L surfactant I, 1-100 g / L surfactant II and 1-50 g / L preservative agent; and the reagent R2 comprises the following components of the corresponding concentrations: 10-100 mmol / L buffer solution II, 0.1-10 mmol / L 4-aminoantipyrine, 1-100 g / L surfactant III, 0.1-10 KU / L cholesterase, 0.1-10 KU / L cholesterol oxidase, 0.1-10 KU / L peroxidase and 1-50 g / L preservative agent. According to the invention, improvement is made on the basis of a selective inhibition method; the preferable compound surfactant pairs are added to inhibit and eliminate lipemia interference in the first reaction step, so that lipemia samples can be directly detected by a full-automatic biochemical analysis instrument without being pretreated; and the kit is simple to operate, improves the detection efficiency and lowers the detection cost.

The invention relates to a kit for measuring high-density lipoprotein cholesterol. The kit comprises a first reagent and a second reagent, wherein the first reagent comprises a surface active agent I used for inhibiting the dissolution of non-high-density lipoprotein (NHDL), and a surface active agent II used for dissolving high-density lipoprotein (HDL); after the surface active agent I is mixed with the surface active agent II, the value of hydrophile-lipophile balance (HLB) is within the range of 13-14; the volume ratio of the surface active agent I to the surface active agent II in the first reagent is (1:30)-(1:1). Due to the synergistic effect of components, the stability of the kit is improved, and the HDL can be specifically released; furthermore, the dissociation of the NHDL can be specifically masked and inhibited, the interference of other components in serum can be eliminated, and the accuracy of measurement is guaranteed.

The invention discloses an isoquinoline derivant. The said derivant, with 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline -7-ylidehydrochlorate (I) as its representative, reduces plasma cholesterol level by massively absorbing low density lipoprotein cholesterol and changing them to bile acid in liver. The 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline-7-ylidehydrochlorate is a new cholesterol lowering compound which is different in cholesterol lowering mechanism from statins. The 9,10-dimethoxy -[1,3] dioxide [4,5-g] isoquinoline [3,2-a] isoquinoline -7-ylidehydrochlorate and other isoquinoline derivants have an extremely low side toxiceffect, so they are safe natural cholesterol lowering compounds.

The invention discloses lactobacillus plantarum ZJUF T17 and application thereof and belongs to the technical field of biology. The lactobacillus plantarum ZJUF T17 is separated from sour dough and has a preservation number of CCTCC (China Center For Type Culture Collection) NO: M 2017342. The lactobacillus plantarum ZJUF T17 provided by the invention has a very high survival rate and a relativelystrong stomach and intestine adhesive force and can be used for remarkably inhibiting reproduction of gastrointestinal tract pathogenic bacteria; the lactobacillus plantarum can be used for remarkably reducing the content of cholesterol in blood serum and optimizing the ratio of high density lipoprotein cholesterol and low density lipoprotein cholesterol; the lactobacillus plantarum can be used for remarkably reducing the content of TNF (Tumor Necrosis Factor)-alpha in the blood serum and has an immunological regulation function; the lactobacillus plantarum has the capability of alleviating the increasing of body weight; furthermore, the lactobacillus plantarum has the potential of preparing fermented milk.

The invention relates to an in-vitro diagnostic reagent for a homogeneous method of low-density lipoprotein cholesterol (LDL-C) of serum, wherein the in-vitro diagnostic reagent is capable of being widely applied to the technical field of medicine and biochemistry and is characterized in that the in-vitro diagnosis is carried out by means of a method comprising the following steps of: step one, selectively cracking chyle particles (CM), very low density lipoprotein cholesterol (VLDL-C) and high density lipoprotein cholesterol (HDL-C) within the serum by using a group of surfactant comprising trimethyl-beta-cyclodextrin, ethylene oxide octadecyl amine, poloxamer F88 and Brij-58, then generating hydrogen peroxide (H2O2) during the catalytic reaction of cholesterol esterase (COE) and cholesterol oxidase (COD), and then discomposing the H2O2 by means of a chemiluminescence clearing system of hydrogen peroxide, wherein the LDL-C particles within the serum are still kept perfectly at the moment; step two, reacting the LDL-C by catalyzing with the COE and the COD under the effect of TritonX-100 so as to generate H202, then promoting a chemiluminescence quantitative system to produce chemiluminescence by catalyzing the H2O2 with POD, and quantitating the LDL-C after measuring luminous intensity. The measuring reagent provided by the invention has the advantages that the sensitivity is high, the capacity of resisting disturbance is strong, the purpose for detecting the LDL-C of serum in batch is realized on a microporous plate chemiluminescence apparatus by measuring chemiluminescence intensity, and the reagent is suitable for the application in clinical laboratory.

The invention discloses functional camellia oil, which is obtained by mixing, stirring and filtering raw materials comprising the following ingredients in parts by mass: 928.8 to 989.3 parts of camellia oleifera seed oil, 10 to 70 parts of plant sterol ester, 0.1 to 0.7 part of rosemary and 0.1 to 1 part of vitamin E. The functional camellia oil has the advantages that the stability is good, the shelf life is long, the effect of obviously reducing blood cholesterol, triglyceride and low-density lipoprotein cholesterin is realized, the cardiovascular and cerebrovascular diseases can be effectively prevented, and good stability is realized during high-temperature cooking.

Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates. The detectable product is measured at different times after assay initiation. A lipase, cholesterol esterase, cholesterol oxidase and a peroxidase may be used together to produce colored product in amounts directly proportional to the quantity of cholesterol converted. Methods for calculating very-low density lipoprotein cholesterol levels by further including triglyceride measurements are disclosed. Assays may be performed in a single reaction mixture, allowing more accurate and precise cholesterol determinations, including ratios of cholesterol sub-fractions to total cholesterol, at less expense, than would be expected by performing several different assays in different reaction mixtures.

The invention relates to a preparation method of a bitter gourd peptide arabinose composite tablet. The bitter gourd peptide arabinose composite tablet consists of the following components in parts by weight: 8-15 parts of bitter gourd polypeptides, 15-25 parts of L-arabinose, 0.1-0.3 part of chromium-enriched yeast, 25-35 parts of inulin, 5-15 parts of phytosterol, 10-15 parts of D- mannitol, 10-20 parts of microcrystalline cellulose, 0.5-1 part of magnesium stearate, and 2-5 parts of hydroxypropyl methylcellulose. The preparation method has beneficial effects that the bitter gourd peptide arabinose composite tablet is prepared by adopting a plurality of components beneficial to blood sugar control and blood lipid metabolism; compared with a way of independently adopting the bitter gourd polypeptides, the inulin or the phytosterol, and the like, a way of combining the bitter gourd polypeptides, the inulin or the phytosterol, and the like is better in effect, beneficial to blood sugar control and blood lipid metabolism of a patient with diabetes mellitus II, and free of influences on functions of livers and kidneys. Besides, the preparation method can improve sensibility of insulin better and can remarkably lower total cholesterol and low-density lipoprotein cholesterol of the patient with diabetes mellitus II.

PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

This invention discloses an associating determination and reagent about high and low-density lipoprotein cholesterol. It utilizes affinity difference between lipoprotein and surface activator, adds agent one and agent two, and with the action of the assembling ionic surface activator, the CM, VLDL and LDL-C or HDL-C in the serum form the soluble complex, the extricate cholesterol generates H#-[2]O#-[2] with the catalytic reaction of cholesterol esterase (CHER) and cholesterol oxidase (CHO), and with the action of peroxydase (POD), the H#-[2]O#-[2] is cleared, and adds agent three, as with the action of a specific selective surface activator, only HDL-C or LDL-C granule is soluble, so with action of Trinder one can determine the content of HDL-C and LDL-C.

Quinoline and quinoxaline compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

The invention discloses compound nutritional noodles and a preparation method thereof. The compound nutritional noodles are prepared by taking perilla frutescens, se-enriched mushrooms and buckwheat as main raw materials, wherein the organic selenium content of the compound nutritional noodles reaches 200 mu g / kg, and the alpha linolenic acid content of the compound nutritional noodles reaches 2%. The preparation method comprises the steps of: (1) preparation of se-enriched mushroom powder or se-enriched malt powder; (2) preparation of perilla frutescens pulp; (3) preparation of buckwheat powder; (4) determination of a formula of the nutritional noodles; and (5) preparation of the noodles. Research proves that due to the reasonable collocation of the perilla frutescens pulp, the se-enriched mushroom powder or the se-enriched malt powder and the buckwheat powder, strong nutrition and health care functions can be brought into play in the aspects of regulating the fat metabolism, enhancing the immunoregulation, reducing the high blood fat and low-density lipoprotein cholesterol, eliminating lead and detoxifying, protecting the liver and heart and blood vessels, and the like. Therefore, the compound nutritional noodles disclosed by the invention have the function of compound nutrition, increase the diet varieties, and can promote the health of people. The compound nutritional noodles are suitable for adults and children to eat.

The invention discloses a preparation method and application of spirulina whole active substances. Spirulina is used as a raw material. The spirulina whole active substances are extracted and prepared by the method of performing extraction with solvents of different polarities (from small to large), performing enzymolysis with compound proteinases and the like, and are prepared through the following steps of firstly performing extraction with 85-95wt% ethanol, then performing extraction with 55-65wt% ethanol, then performing water extraction, finally performing enzymolysis on water extraction residues, then performing centrifuging, performing filtration, performing decompression, performing concentration, and performing drying so as to obtain a spirulina 85-95wt% ethanol extract, a spirulina 55-65wt% ethanol extract, a spirulina water extract and a spirulina zymolyte, namely the spirulina whole active substances. Pharmacodynamics experiments verify that the whole active substances can significantly improve lipid metabolism disorder induced by high fat diet, and specifically, can significantly reduce the level of total cholesterol (TC), the level of triglyceride (TG) and the level of low density lipoprotein cholesterol (LDL-C) in serum.

The invention provides a reagent for directly and quantitatively determining low-density lipoprotein cholesterol (LDL-C) in human serum in a homogeneous system by an enzymatic method. The reagent is suitable for automatically and quantitatively determining the LDL-C by an automatic biochemical analyzer. The reagent consists of a solution type reagent 1 and a solution type reagent 2 which are placed separately, wherein the reagent 1 contains cholesterol esterase, cholesterol oxidase, 4-amino-antipyrine, catalase, surfactant, a buffering agent and a stabilizing agent; and the reagent 2 comprises peroxidase, a color-developing agent, the other surfactant, a stabilizing agent and a buffering agent. The invention also provides a method for directly determining the content of the LEDL-C in the homogeneous system without pre-treating a serum sample, and a kit which specifically uses the method in a clinical laboratory and in which the reagent 1 and the reagent 2 are accommodated.

The invention provides mytilus edulis polysaccharide extracted from mytilus sp., an industrial extraction method of the mytilus edulis polysaccharide, and an application of the mytilus edulis polysaccharide in preparation of antilipemic and antiatherosclerotic drugs and health food. The mytilus edulis polysaccharide takes (1-4)-alpha-D-Glc as main chains, contains (1-2)-alpha-D-Glc branches, and has a configuration of alpha-pyranoid glucan; every 12 glucose main chains averagely contain one (1-2) glucose branch; and the relative molecular weight is 800-8000KDa. The mytilus edulis polysaccharide is extracted from boiled and dried mytilus sp. by coarse extraction, enzymolysis, purification, drying and the like, and is mild in extraction condition and high in purity. The mytilus edulis polysaccharide can significantly reduce triglyceride, total cholesterol and low-density lipoprotein cholesterol, has an effect of reducing lipid, and is widely applied to preparation of drugs for treating or preventing hyperlipoidemia and atherosclerosis and preparation of antilipemic health products or special medical formula food.

A reagent for the content of the low density lipoprotein cholesterol in the quantitative determining serum sample, consists of the reagent I and reagent II that places respectively, the reagent I contains the styrylphenol polyoxyethylene ether and the quantitative enzyme reagent; the reagent II contains the reaction accelerant. The invention provides a reagent box with the reagent I and the reagent II, and a method for determining the low density lipoprotein cholesterol content.

The invention discloses bifidobacterium pseudocatenulatum CCFM1046, a composition, a fermented food, applications, a microbial inoculum and a preparation method thereof. As the bifidobacterium pseudocatenulatum CCFM1046 can tolerate gastrointestinal environments in human bodies, the rising of hepatic triglyceride content of metabolic syndrome mice caused by high-fat diet can be significantly improved; the weight increasing of the metabolic syndrome mice can be alleviated; the abnormal fasting blood glucose and oral glucose tolerance of the metabolic syndrome mice can be significantly improvedas well; area under the curve of glucose tolerance can be reduced; serum insulin levels can be enhanced; the rising of low-density lipoprotein cholesterol in serum of the metabolic syndrome mice caused by the high-fat diet can be significantly improved; and the rising of Proteus genus in intestinal tracts caused by the high-fat diet can also be significantly improved. The bifidobacterium pseudocatenulatum CCFM1046 can be used for preparing the pharmaceutical composition and fermented food for alleviating metabolic syndromes and decreasing the occurrence of Parkinson, intestinal infection, urinary tract and kidney infection and other diseases, so that the bifidobacterium pseudocatenulatum CCFM1046 can have very wide application prospects.

The invention discloses a method and reagent for detecting small and dense low-density lipoprotein cholesterol (sdLDL-C) in a sample. The method is characterized by comprising the steps of (1) eliminating cholesterol, except the sdLDL-C, in lipoproteins in the sample first in the presence of cholesterol esterase and an ion selective agent; and (2) conducting quantitative detection on remaining sdLDL-C obtained after treatment in step (1). The ion selective agent is used to selectively eliminate lipoproteins other than the sdLDL-C, so as to detect the sdLDL-C.

A lipid-lowering tea and a production method relate to the production process of bagged tea. The invention mainly comprises raw hawthorns, cassia seeds, lotus leaves and black tea. The invention can obviously inhibit the increase of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and atherosclerosis index (CAI) of serum, improve the high-density lipoprotein cholesterol (HDL-C) and anti-atherogenic index (AI), prevent fatty liver degeneration, slow and inhibit the formation of atherosclerotic plaque. The tea is of food class, which ensures the taste and has the specific effect; long-term tea drinking causes no toxic side effects; besides, the lipid-lowering tea is convenient and can be used in daily life, working, tourism and leisure time, and the user can enjoy health-care in tea drinking.